Article
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.
Nature communications - 2 Jul 2021
He Chen, Xu Ke, Zhu Xiaoyan, Dunphy Paige S, Gudenas Brian, Lin Wenwei, Twarog Nathaniel, Hover Laura D, Kwon Chang-Hyuk, Kasper Lawryn H, Zhang Junyuan, Li Xiaoyu, Dalton James, Jonchere Barbara, Mercer Kimberly S, Currier Duane G, Caufield William, Wang Yingzhe, Xie Jia, Broniscer Alberto, Wetmore Cynthia, Upadhyaya Santhosh A, Qaddoumi Ibrahim, Klimo Paul, Boop Frederick, Gajjar Amar, Zhang Jinghui, Orr Brent A, Robinson Giles W, Monje Michelle, Freeman Iii Burgess B, Roussel Martine F, Northcott Paul A, Chen Taosheng, Rankovic Zoran, Wu Gang, Chiang Jason, Tinkle Christopher L, Shelat Anang A, Baker Suzanne J
Abstract excerpt
Pediatric high-grade glioma (pHGG) is a major contributor to cancer-related death in children. In vitro and in vivo disease models reflecting the intimate connection between developmental context and pathogenesis of pHGG are essential to advance understanding and identify therapeutic vulnerabilities. Here we report establishment of 21 patient-derived pHGG orthotopic xenograft (PDOX) models and eight matched cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.